Menu
 
Research menu
Jump to menu

Publications:  Mr Sabarinath Vallath

Whilding LM, Parente-Pereira AC, Zabinski T, Davies DM, Petrovic RMG, Kao YV, Saxena SA, Romain A et al.(2017). Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells. Molecular Therapy vol. 25, (1) 259-273.
10.1016/j.ymthe.2016.10.012
https://qmro.qmul.ac.uk/xmlui/handle/123456789/49611
Whilding LM, Vallath S, Maher J(2016). The integrin αvβ6: a novel target for CAR T-cell immunotherapy?. Biochem Soc Trans vol. 44, (2) 349-355.
10.1042/BST20150249
Vallath S, Sage EK, Kolluri KK, Lourenco SN, Teixeira VS, Chimalapati S, George PJ, Janes SM et al.(2016). CADM1 inhibits squamous cell carcinoma progression by reducing STAT3 activity. Scientific Reports vol. 6, (1) Article 24006,
10.1038/srep24006
Vallath S, Hynds RE, Succony L, Janes SM, Giangreco A(2014). Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities. European Respiratory Journal vol. 44, (2) 513-522.
10.1183/09031936.00146413
Moore KM, Thomas GJ, Duffy SW, Warwick J, Gabe R, Chou P, Ellis IO, Green AR et al.(2014). Therapeutic targeting of integrin αvβ6 in breast cancer. Journal of the National Cancer Institute vol. 106, (8)
10.1093/jnci/dju169
https://qmro.qmul.ac.uk/xmlui/handle/123456789/8829
Allen MD, Thomas GJ, Clark S, Dawoud MM, Vallath S, Payne SJ, Gomm JJ, Dreger SA et al.(2013). Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of αvβ6 integrin in DCIS identifies high-risk patients and predicts recurrence. Clin Cancer Res vol. 20, (2) 344-357.
10.1158/1078-0432.CCR-13-1504
Coughlan L, Vallath S, Gros A, Giménez-Alejandre M, Van Rooijen N, Thomas GJ, Baker AH, Cascalló M et al.(2012). Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5. Hum Gene Ther vol. 23, (9) 960-979.
10.1089/hum.2011.218
Allen MD, Vaziri R, Green M, Chelala C, Brentnall AR, Dreger S, Vallath S, Nitch-Smith H et al.(2011). Clinical and functional significance of α9β1 integrin expression in breast cancer: A novel cell-surface marker of the basal phenotype that promotes tumour cell invasion. Journal of Pathology vol. 223, (5) 646-658.
10.1002/path.2833
Marsh D, Suchak K, Moutasim KA, Vallath S, Hopper C, Jerjes W, Upile T, Kalavrezos N et al.(2011). Stromal features are predictive of disease mortality in oral cancer patients. J Pathol vol. 223, (4) 470-481.
10.1002/path.2830
Filipovi¿ A, Gronau JH, Green AR, Wang J, Vallath S, Shao D, Rasul S, Ellis IO et al.(2011). Biological and clinical implications of nicastrin expression in invasive breast cancer. Breast Cancer Research and Treatment vol. 125, (1) 43-53.
10.1007/s10549-010-0823-1
Marsh D, Suchak K, Moutasim K, Vallath S, Hopper C, Jerjes W, Upile T, Kalavrezos N et al.(2011). Stromal features are predictive of disease mortality in oral cancer patients. J Pathol vol. 4, (223) 470-481.
10.1002/path.2830
Marsh D, Suchak K, Moutasim KA, Vallath S, Hopper C, Jerjes W, Upile T, Kalavrezos N et al.(2010). Stromal features are predictive of disease mortality in oral cancer patients. J Pathol
10.1002/path.2830
Wagstaff JL, Vallath S, Marshall JF, Williamson RA, Howard MJ(2010). Two-dimensional heteronuclear saturation transfer difference NMR reveals detailed integrin αvβ6 protein-peptide interactions. Chem Commun (Camb) vol. 46, (40) 7533-7535.
10.1039/c0cc01846e
Saha A, Ellison D, Thomas GJ, Vallath S, Mather SJ, Hart IR, Marshall JF(2010). High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin αvβ6. Journal of Pathology vol. 222, (1) 52-63.
10.1002/path.2745
Coughlan L, Vallath S, Saha A, Flak M, McNeish IA, Vassaux G, Marshall JF, Hart IR et al.(2009). In vivo retargeting of adenovirus type 5 to αvβ6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. Journal of Virology vol. 83, (13) 6416-6428.
10.1128/JVI.00445-09
Return to top